louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00065208: Reiki/Energy Healing in Prostate Cancer
Official title: Effects of Energy Healing on Prostate Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Prostate Cancer
Keywords: Prostate cancer
Reiki
Energy Healing
Lead sponsor: The Cleveland Clinic
Sponsor class: OTHER
Collaborators: name: National Center for Complementary and Integrative Health (NCCIH)
First posted: 2003-07-22
Enrollment: 79
Sex: MALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether Reiki energy healing affects anxiety and disease progression in patients with localized prostate cancer who are candidates for radical prostatectomy.

Detailed description: 120 newly diagnosed prostate cancer patients will be randomized to one of 3 groups: Reiki, another touch therapy, or guided imagery. Subjects in the Reiki and touch therapy groups have 8 sessions in the 4 weeks prior to their medical intervention. Those in the imagery group have one session prior to their medical intervention.

Eligibility criteria: Inclusion criteria:

* Newly diagnosed with prostate cancer
* Scheduled for radial prostatectomy, external beam radiation, brachytherapy, or a combination of these

Exclusion criteria:

* Already involved in energy healing treatments
* Any patient whose medical intervention could not wait the 4-weeks for intervention for medical reasons
* Any patient who gets neo-adjuvant therapy or any herbal product that could affect PSA

Primary outcomes:
measure: To evaluate the effects of Reiki on anxiety states using validated psychometric instruments.
timeFrame: Each 30 minute session
measure: To evaluate the effects of Reiki on physiologic anxiety as measured by cortisol and DHEA levels
timeFrame: Each 30 minute session
measure: To evaluate the effects of Reiki on cancer progression as measured by PSA levels in plasma.
timeFrame: throughout study
Secondary outcomes:
measure: To evaluate the effects of Reiki and guided imagery on post-surgical pain and urinary symptoms
timeFrame: Throughout study
Other outcomes:
Locations:
city: Cleveland
country: United States
facility: Cleveland Clinic Foundation
state: Ohio
Study officials:
affiliation: The Cleveland Clinic
name: Joan Fox, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05473208: Lumbar Assistive Exoskeletons in Caregiving
Official title: "Effectiveness of Lumbar Assistive Exoskeleton in Nursing Home Caregivers: Randomized Control Trial"
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Healthy
Low Back Pain
Musculoskeletal Pain
Musculoskeletal Injury
Keywords: Low back pain
Exoskeleton
Caregiver
Nursing home
Musculoskeletal disease
Quality of life
Lead sponsor: University of the Basque Country (UPV/EHU)
Sponsor class: OTHER
Collaborators: name: Diputación Foral de Bizkaia
First posted: 2022-07-25
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: A randomized control trial will be conducted, for evaluating the effectiveness of the implementation of a lower back assistive exoskeleton on the caregivers working in nursing homes.


Eligibility criteria: Inclusion Criteria:

* nursing home caregivers

Exclusion Criteria:

* pregnancy
* presence of condition that prevents from the use of a lumbar exoskeleton

Primary outcomes:
measure: Change from baseline Pain Intensity at 3 months
timeFrame: At Baseline and at 3 months
measure: Change from baseline Pain Intensity at 6 months
timeFrame: At Baseline and at 6 months
measure: Change from baseline Pain Intensity at 9 months
timeFrame: At Baseline and at 9 months
measure: Change from baseline Pain Intensity at 12 months
timeFrame: At Baseline and at 12 months
Secondary outcomes:
measure: Usability measured by System Usability Scale
timeFrame: Baseline, month 3, month 6, month 9, post intervention
measure: User Satisfaction measured by Quebec User Evaluation of Satisfaction with Assistive Technology
timeFrame: Baseline, month 3, month 6, month 9, post intervention
measure: Self-reported work ability by Work Ability Index
timeFrame: Baseline, month 3, month 6, month 9, post intervention
measure: Borg's CR-10 scale for perceived physical exertion at work
timeFrame: Baseline, month 3, month 6, month 9, post intervention
measure: Muscular resistance of the trunk muscles measured by the "Shirado-Ito" test
timeFrame: Baseline, month 3, month 6, month 9, post intervention
measure: Discomfort measured by Body Part Discomfort Scale
timeFrame: Baseline, month 3, month 6, month 9, post intervention
measure: Absenteeism
timeFrame: Baseline, month 3, month 6, month 9, post intervention
measure: Musculoskeletal disorders prevalence
timeFrame: Baseline, month 3, month 6, month 9, post intervention
measure: Prevalence of Side Effects
timeFrame: Baseline, month 3, month 6, month 9, post intervention
Other outcomes:
Locations:
city: Leioa
country: Spain
facility: IFAS/GUFE Centro Asistencial Leioa
state: Bizkaia
city: Elorrio
country: Spain
facility: IFAS/GUFE Centro Asistencial Elorrio
state: Vizcaya
Study officials:
affiliation: Professor
name: Ana Rodriguez Larrad, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT05369923: Survey of Knowledge and Attitude of Pain in Anesthesia Residents of Thailand
Official title: Survey of Knowledge and Attitude of Pain in Anesthesia Residents of Thailand
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Pain
Lead sponsor: Prince of Songkla University
Sponsor class: OTHER
First posted: 2022-05-11
Enrollment: 140
Sex: ALL
Minimum age (years): 22
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Anesthesia residents in Thailand

Brief summary: This study is a prospective descriptive cross-sectional survey using the modified Knowledge and Attitudes Survey Regarding Pain (KASRP) in English via an online google form.

Detailed description: Setting of the study/Trial site This study will be conducted via google form survey.

Target population (Provide a complete description of your target population in the study) Anesthesia residents of all levels throughout Thailand.

Study population (Provide details of your population in the study) Anesthesia residents of all levels throughout Thailand.

Inclusion criteria Anesthesia residents of all levels throughout Thailand.

Exclusion criteria Anesthesia residents who do not want to participate in this study.

Withdrawal criteria (e.g. research participant withdrawal, adverse outcome during participating the study) Anesthesia residents can stop answering the questionnaire survey at any time.

Termination criteria (e.g. terminating investigational product treatment/trial treatment) Not relevant

Eligibility criteria: Inclusion Criteria:

* Anesthesia residents of all levels throughout Thailand.

Exclusion Criteria:

* Anesthesia residents who do not want to participate in this study.

Primary outcomes:
measure: Pain knowledge
timeFrame: Through study completion, an average of 1 year
Secondary outcomes:
measure: Pain attitude
timeFrame: Through study completion, an average of 1 year
Other outcomes:
Locations:
Study officials:
References:
citation: Kim MH, Park H, Park EC, Park K. Attitude and knowledge of physicians about cancer pain management: young doctors of South Korea in their early career. Jpn J Clin Oncol. 2011 Jun;41(6):783-91. doi: 10.1093/jjco/hyr043. Epub 2011 Apr 18.
Clinical trial NCT06513923: Comparison of Remimazolam and Propofol on Emergence in Elderly Orthopedic Patients Under General Anesthesia
Official title: Comparative Study of Remimazolam, Remimazolam Plus Flumazenil vs Propofol Anesthesia on Emergence Time in Elderly Patients Undergoing Hip Replacement: A Randomized, Double Blinded Controlled Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Hip Fracture
Lead sponsor: Central South University
Sponsor class: OTHER
First posted: 2024-07-22
Enrollment: 136
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Purpose: This study aims to compare the emergence time among three anesthesia regimens: remimazolam, remimazolam with flumazenil, and propofol in elderly patients undergoing hip replacement surgery.

Background: Previous studies have shown that flumazenil accelerates emergence time when used with remimazolam. Remimazolam and propofol have comparable emergence times, although remimazolam can be up to 5 minutes longer than propofol.


Eligibility criteria: Inclusion Criteria:

* Elderly patients (≥65 years old).
* Scheduled for elective hip replacement surgery.
* ASA (ASA, American Society of Anesthesiologists) physical status I-III.
* Able to provide informed consent.

Exclusion Criteria:

* Known hypersensitivity to remimazolam, flumazenil, or propofol.
* Severe hepatic or renal impairment.
* History of benzodiazepine or alcohol abuse.
* Cognitive impairment that may interfere with the ability to provide consent.

Primary outcomes:
measure: Time to Emergence
timeFrame: Within one day of surgery
Secondary outcomes:
measure: Hemodynamic Parameters
timeFrame: During operation
measure: Hemodynamic Parameters
timeFrame: During operation
measure: Post-Operative Recovery
timeFrame: Within one day of surgery
measure: Adverse Events
timeFrame: Within one day of surgery
Other outcomes:
Locations:
city: Changsha
country: China
facility: Department of Anesthesiology, The Second Xiangya Hospital
state: Hunan
city: Changsha
country: China
facility: The Second Xiangya Hospital
state: Hunan
Study officials:
affiliation: Central South University
name: Ru-Ping MD Dai, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00418223: Detecting Urinary Retention After Child Birth With a Ultrasound Scanner
Official title: Detecting Urinary Retention After Child Birth With a Ultrasound Scanner
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Urinary Retention
Keywords: Urinary retention
Child birth
Catheterization
Ultrasound
Lead sponsor: Oslo University Hospital
Sponsor class: OTHER
First posted: 2007-01-04
Enrollment: 100
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Women after childbirth

Brief summary: The purpose of this study is a systematical registration of ultrasound measurements and urinary volume after catheterization. Based on these pairs of measurements we will calculate the reliability of ultrasound compared with catheter volume.


Eligibility criteria: Inclusion Criteria:

* Women with suspected urinary retention

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Oslo
country: Norway
facility: Rikshospitalet-Radiumhospitalet HF
Study officials:
affiliation: Oslo University Hospital
name: Leiv A Rosseland, MD
role: STUDY_DIRECTOR
References:
citation: Lukasse M, Cederkvist HR, Rosseland LA. Reliability of an automatic ultrasound system for detecting postpartum urinary retention after vaginal birth. Acta Obstet Gynecol Scand. 2007 Oct;86(10):1251-5. doi: 10.1080/00016340701621478.
Clinical trial NCT03756623: Effect of Metformin and Probiotics on Gut Microbiome in Healthy Subjects
Official title: Effect of Metformin and Probiotics on Gut Microbiome in Healthy Subjects: a Randomized, Double-blind Study.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Lead sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Sponsor class: OTHER
First posted: 2018-11-28
Enrollment: 90
Sex: ALL
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: This clinical trial is designed to evaluate the alteration of gut microbiome in healthy subjects after a 12-week metformin and/or probiotics administration.

Detailed description: Gut microbiome dysbiosis have been linked with the onset and progression of several diseases. Metformin and probiotics have been confirmed to function partly by regulating the gut microbiome. The investigators are now wondering if metformin/probiotics treatment will change the gut microbiota in healthy subjects and show some benefits.

In this study, about 60 healthy subjects will be enrolled. Participants will be randomly assigned into one of the following three groups: Metformin powder (0.5g tid po), Probiotics powder (0.5g tid po), Placebo powder (0.5g tid po), for 12 weeks.

Blood and stool samples will be collected before and after treatment. Fasting glucose levels, fasting insulin levels, serum lipid profiles, inflammation markers and alteration of gut microbiota will be evaluated.

Eligibility criteria: Inclusion Criteria:

1. Between 20-60 years of age.
2. Healthy subjects without known diseases.

Exclusion Criteria:

1. During pregnancy and lactation period.
2. Impaired liver function, impaired renal function, mental disease, severe infection, severe anemia, severe heart disease and neutropenia disease.
3. Use of metformin/antibiotics within 3 months.
4. Immunodeficient or use of immunosuppressive drugs.
5. Previous history of gastrointestinal surgery or diseases (such as peptic ulcer, irritable bowel syndrome, inflammatory bowel disease or other gastrointestinal disorder).
6. Medical conditions or diseases that may affect subject safety or confound study results in the opinion of the investigator.

Primary outcomes:
measure: Gut microbiota alterations
timeFrame: 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Nanjing
country: China
facility: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
state: Jiangsu
Study officials:
affiliation: Drum Tower hospital affiliated to Nanjing University Medical School
name: Mingming Zhang, MD,PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00584623: Simultaneous Fluoroscopic and Endoscopic Examination of the Oropharyngeal Phase of Deglutition
Official title: Simultaneous Fluoroscopic and Endoscopic Examination of the Oropharyngeal Phase of Deglutition
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Dysphagia
Keywords: dysphagia
videofluoroscopy
flexible endoscopic evaluation
Lead sponsor: University of California, Davis
Sponsor class: OTHER
First posted: 2008-01-02
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Adult clinic population in the UCD Otolaryngology Clinic

Brief summary: To correlate findings between two commonly-used types of swallowing studies: videofluoroscopy and flexible endoscopic evaluation of swallowing (FEES).

Detailed description: The specific aim of this study is to correlate findings between two commonly-used types of swallowing studies: videofluoroscopy and flexible endoscopic evaluation of swallowing (FEES). Specifically, the timing of swallowing events will be correlated between teh two studies. In addition, the pharyngeal constriction ratio (a validated measure of pharyngeal strength on videofluoroscopy) will be compared with the pharyngeal squeeze maneuver (an assessment of pharyngeal strength on FEES), with the hypothesis that there will be a strong correlation between PCR and pharyngeal squeeze.

Eligibility criteria: Inclusion Criteria:

* complaints of dysphagia
* scheduled to undergo videofluoroscopy
* able to tolerate both videofluoroscopic evaluation of swallowing and FEES

Exclusion Criteria:

* age less than 18
* contraindications to videofluoroscopy (reaction to barium, possible pregnancy)
* contraindications to FEES (bilateral obstructing nasal pathology or nasopharyngeal stenosis)
* specific/vulnerable populations (children, mentally handicapped, pregnant women, fetuses, prisoners, cognitive impairment, life-threatening disease, social or economic disadvantage)

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Sacramento
country: United States
facility: University of California Davis Medical Center
state: California
Study officials:
affiliation: University of California, Davis
name: Peter C. Belafsky, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01897623: Prevalence and Screening of Abdominal Aortic Aneurysms Among Men With Coronary Artery Disease
Official title: Prevalence and Screening of Abdominal Aortic Aneurysms Among Men With Coronary Artery Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Abdominal Aortic Aneurysm
Lead sponsor: North Karelia Central Hospital
Sponsor class: OTHER
Collaborators: name: Kuopio University Hospital
name: Tampere University Hospital
First posted: 2013-07-12
Sex: MALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Primary purpose: SCREENING

Brief summary: The purpose of this study is to investigate the prevalence of abdominal aortic aneurysms (AAA) among male patients with coronary artery disease (CAD) verified in coronary angiography. Ethiology of AAA is known to be common with atherosclerotic arterial diseases (coronary artery disease, peripheral artery disease and carotid artery disease), so the hypothesis is that AAA should be more common among these CAD patients, thus making screening of these patients (for AAA) more cost-efficient.

Study will be carried out as a multi-center prospective screening study. Data will be collected in North Karelia Central Hospital, Kuopio University Hospital and Tampere University Hospital. Data consists of 200 consecutive coronary angiography patients in each hospital, resulting in 600 patients in total. All male patients with diagnosed CAD will be recruited for the study and screened for AAA with ultrasound. Nevertheless, patients with previously known AAA will be excluded from the study.


Eligibility criteria: Inclusion Criteria:

* Male patients with coronary artery disease

Exclusion Criteria:

* Patient's denial to participate
* Female Gender
* Already diagnosed or treated abdominal aortic aneurysm

Primary outcomes:
measure: Maximum diameter (mm) of abdominal aorta (outer-to-outer wall) in ultrasound
timeFrame: upon screening
Secondary outcomes:
Other outcomes:
Locations:
city: Joensuu
country: Finland
facility: North Carelia Central Hospital
state: Pohjois-Karjala
Study officials:
References:
Clinical trial NCT04366323: Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19
Official title: Phase I / II Clinical Trial, Multicenter, Randomized and Controlled, to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Sars-CoV2
Lead sponsor: Andalusian Network for Design and Translation of Advanced Therapies
Sponsor class: OTHER
First posted: 2020-04-28
Enrollment: 26
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Phase I/II clinical trial to evaluate the safety and efficacy of Allogenic Adipose Tissue-Derived Mesenchymal Stem Cells Expanded in patients with severe COVID-19 pneumonia


Eligibility criteria: Inclusion Criteria:

1. Age ≥ 18
2. Clinical diagnosis of Pneumonia, severe or critical, caused by COVID-19 infection
3. Life expectancy \> 48 hours.
4. Commitment to use a contraceptive method of proven efficacy in both men and women during the duration of the clinical trial.

Exclusion Criteria:

1. Coinfection with other viruses or bacteria (HIV, tuberculosis, influenza virus, adenovirus or other respiratory infections, active infection by HBV or C).
2. History of multiple allergies, including allergy to Penicillin or other Blactams.
3. Pregnant and lactating women.
4. Patients with malignant tumors or hemopathies or any state of immunosuppression considered as severe.
5. Patients with autoimmune diseases.
6. Chronic heart failure with ejection fraction less than 30%.
7. Any other condition for which, in the opinion of the main investigator, the subject is considered not to be in compliance with the study.

Primary outcomes:
measure: Safety of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Adverse Event Rate
timeFrame: 12 months
measure: Efficacy of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Survival Rate
timeFrame: 28 days
Secondary outcomes:
Other outcomes:
Locations:
city: Jerez de la Frontera
country: Spain
facility: Hospital Universitario de Jerez de la Frontera
state: Cádiz
city: Córdoba
country: Spain
facility: Hospital Reina Sofía
city: Granada
country: Spain
facility: Hospital Universitario Virgen de las Nieves
city: Sevilla
country: Spain
facility: Hospital Universitario Virgen Macarena
city: Sevilla
country: Spain
facility: Hospital Unversitario Virgen del Rocío
city: Sevilla
country: Spain
facility: Hospital Nuestra Señora de Valme
Study officials:
References: